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Abstract By using a new tobacco mosaic virus (TMV) vector 
[Hamamoto, H., et al. (1993) Biofrechnoiogy 11,930-932], we 
have constructed TMV particles which present three different 
kinds of epitopes, two of them from influenza virus hemagglutinin 
(HA), and one from human immunodeficiency virus type I (HIV- 
I) envelope protein, on the surface of the particles. Each of these 
TMV particles reacted with each anti-peptide antiserum. These 
results suggest hat this TMV vector can be used as an antigen 
presentation system. 
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I. Introduction 
An attractive approach for an effective peptide vaccine is 
presenting an epitope on the surface of a particle structure, and 
considerable interest has been focused on the biochemical link- 
ing of the epitope to a carrier protein which is able to form a 
particle structure. The use of virus coat proteins of bacteria 
[1 3], animals [4-7] and plants [8-10] as carrier proteins has 
been reported. Recently, it has been shown that cowpea mosaic 
virus (CPMV) in which epitopes from animal viruses were in- 
serted into the small coat protein, can present he epitopes on 
the surface of the virus particle, and the inserted epitopes are 
immunogenic n rabbits [10]. 
We have previously developed a tobacco mosaic virus 
(TMV) vector which can produce both intact coat protein (CP) 
and fused protein (FP) consisting of CP and angiotensin I-
converting enzyme inhibitor peptide (ACEI) by inserting a 
translational read-through signal of a 'leaky' UAG (amber) 
stop codon downstream of the CP gene [11]. This vector could 
form virus particles and spread systemically in tobacco and 
tomato plants. Moreover, protein analysis of progeny virus 
particles howed not only the presence of intact CP, but also 
that of FP, CP-ACEI  [11]. Because ACEI was fused to the 
C-terminus of the CP, and the C-terminus portion of the CP 
protrudes outwards from the TMV particle [12,13], it is sus- 
pected that ACEI is located on the surface of the virus particle. 
In this paper, we describe the construction of TMV particles 
which present epitopes from influenza nd human immunodefi- 
ciency viruses on the surface of the particles. The peptide se- 
quences used for the particles consisted of residues 91 108 
(pepl8), 139-146 (pepS) from influenza virus HA [14], and the 
principal neutralization determinant consisting of 13 residues 
(pepl3) from HIV-I gpl20 [15]. It has been shown that antibod- 
ies against these peptides had binding capacity to the virus 
[14,151. 
2. Materials and methods 
2.1. Plasmid construction, in vitro transcription, #toculation of plants, 
and virus particle purification 
The construction ofpTLW3 and pTLRTB has been described previ- 
ously [11]. Pairs of partially complementary oligonucleotides: dGAC- 
CTCTGCACCTGCATCATAGCAATTATCTAAAGCTTTCTCTA- 
ATTGTTACCCTTACGATGTTCCTGATTACGCATCTTTATAA- 
ATGCA and dTTTATAAAGATGCGTAATCAGGAACATCGTA- 
AGGGTAACAATTAGAGAAAGCTTTAGATAATTGCTATGAT- 
GCAGGTGCAGAG for pTLHA1, dGACCTCTGCACCTGCATC- 
ATAGCAATTATGTAAAAGAGGTCCTGATTCTGGTTAAAT- 
GCA and dTTTAACCAGAATCAGGACCTCTTTTACATAATTG- 
CTATGATGCAGGTGCAGAG for pTLHA2, dGACCTCTGCAC- 
CT GC ATC ATA GC AATTAAAATCTA G A ATA C AAA G A GG T CC- 
TGGTAGAGCATTTGTTTAAATGCA and dTTTAAACAAATG- 
CT CTA CC A GG A CCT CTTTGTATT CTA G ATTTTA ATT GCTAT- 
GATGCAGGTGCAGAG for pTLHIV were synthesized, respectively, 
to construct vectors. These oligonucleotides replaced the Avail (posi- 
tion 6160) NsiI (position 6183) fragment of pTLW3 in the same man- 
ner as pTLRT, as described previously [11]. In vitro transcription, 
inoculation of plants, and virus particle purification, were carried out 
as described previously [11]. 
2.2. Western blot analysis 
Samples of 1 ¢tg of virus particle were separated by 12.5% SDS- 
PAGE and the proteins were transferred to PVDF membranes. A 
ProtoBlot Western Blot AP system (Promega) was used for immunode- 
tection. Anti-ACEI, anti-pep 18, anti-pep8 and anti-pep 13 antisera were 
raised in rabbit against synthetic peptid~keyhole limpet hemocyanin 
(KLH) conjugate. 
2.3. Trypsin treatment 
25/tg of purified virus particles or purified free CP were treated with 
0.5/lg of trypsin or without rypsin in 50 mM Tris-HC1 (pH 7,5) buffer 
at 30°C for 5 rain. After treatment with trypsin, 1 ,ug of the virus 
particles was used for Western blot analysis. 
2.4. Precipitin reaction 
A layer of antiserum was covered with a layer of virus particle 
solution at concentrations of 4 mg/ml in 0.2 ml polypropylene tube. 
Photographs were taken after incubation at room temperature for 15 
min. 
3. Results 
*Corresponding author. Fax: (81) (465) 34-3037. 
**Present address: Gene Experiment Center, Tsukuba University, 
Tennoh dai, Tsukuba, Ibaraki 305, Japan. 
3.1. Vector construction 
TMV RNA vectors were transcribed from their template 
plasmids in vitro [11]. pTLW3 [11] is the standard template 
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Fig. I. The sequences around the stop codon for CP genes of template plasmids (pTLW3, pTLRTB, pTLHAI, pTLHA2 and pTLHIV). Amino acids 
are shown under nucleotide sequences by one-letter symbols. In pTLRTB, pTLHA1, pTLHA2 and pTLHIV, the 3' terminal T of the CP gene 
(pTLW3) was changed to A, indicated by filled triangles, to increase the read-through efficiency [1 l]. In pTLRTB, a codon for Arg, AGA, was placed 
between 3' context sequence (3'CS) and the ACEI gene to enable the release of ACEI by treatment with trypsin. The 3'CS allows read-through of
a 'leaky' UAG (amber) stop codon [16]. Asterisks indicate the stop codons. 
plasmid for wild-type TMV RNA. pTLRTB [11] is the template 
plasmid used to produce both intact CP and CP ACEI.  
pTLHA1 was designed for production of both intact CP and 
CP-pepl8.  pTLHA2 was designed for both intact CP and CP  
pep8, and pTLHIV for both intact CP and CP pepl3 (Fig. 1). 
In pTLHA1, pTLHA2 and pTLHIV, oligonucleotides encod- 
ing the peptides were inserted just after the 3' context sequence 
which allows read-through of a 'leaky' UAG (amber) stop 
codon [16]. These RNA transcripts will be referred to by delet- 
ing the prefix 'p' from their template designations. 
3.2. Systemic inJ~,ctivity of TMV vectors in tobacco plants 
To investigate the ability of TLHA1, TLHA2 and TLH1V 
vectors to spread systemically in tobacco plants, 20 ng of TMV 
RNA vectors were encapsidated with CP in vitro and inocu- 
lated onto leaves of five tobacco (Nicotiana tabaeum cv. 
Samsun) plants as described previously [11]. Inoculation of 
these vectors resulted in mosaic symptoms 2 or 3 weeks after 
the inoculation in the upper non-inoculated leaves. By Western 
blot analysis, both intact CP and fused protein were detected 
in the inoculated and upper non-inoculated leaves of TLHAI - ,  
TLHA2- and TLHIV-infected plants (data not shown), as in 
the case of TLRTB-infected plants [11], This result indicates 
that TLHA1, TLHA2 and TLHIV vectors can form virus par- 
ticles and spread systemically in plants, as in the case of TLRTB 
vector. 
3.3. Purification of virus particles 
One month after the inoculation, virus particles were purified 
from upper non-inoculated leaves as described previously [11]. 
From 10 g of tobacco leaves, 18 mg of TLW3, 12 mg of 
TLRTB, 8 mg of TLHA1, 20 mg of TLHA2 and 16 mg of 
TLHIV virus particles were obtained. Proteins in these virus 
particles were examined by Western blot analysis using an anti- 
TMV antiserum. All virus particles, except he TLW3 particles, 
included not only intact CP but also FP (Fig. 2A). To confirm 
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Fig. 2. Western blot analysis of the proteins of virus particles using 
anti-TMV antiserum (A), anti-ACEI (B, lane 1), anti-pepl8 (B, lane 2), 
anti-pep8 (B+ lane 3) and anti-pepl3 (B, lane 4) antiserum. Samples are 
from the virus particles of TLW3 (A, lane 1), TLRTB (A, lane 2; B. lane 
1), TLHA1 (A, lane 3; B, lane 2), TLHA2 (A, lane 4; B, lane 3) and 
TLHIV (A, lane 5; B, lane 4). The positions of CP and FP are shown 
on the left. 
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Fig. 3. Western blot analysis of the proteins of virus particles treated 
with trypsin using anti-TMV antiserum (A), anti-ACEI (B, lanes 5 and 
6), anti-pepl8 (B, lanes 7 and 8), anti-pep8 (B, lanes 9 and 10) and 
anti-pepl3 (B, lanes 11 and 12) antiserum. Samples are from purified 
free CP (lanes 1 and 2), and the virus particles of TLW3 (lanes 3 and 
4), TLRTB (lanes 5 and 6), TLHAI (lanes 7 and 8), TLHA2 (lanes 9 
and 10) and TLHIV (lanes 11 and 12). The samples were treated with 
trypsin (lanes 2, 4, 6, 8, 10 and 12), or without rypsin (lanes 1, 3, 5, 
7, 9 and 11). The positions of CP and FP are shown on the left. 
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particles locate on the surface of the particles, the particles were 
treated with trypsin. An Arg residue was placed just N-termi- 
nus of the ACEI sequence in TLRTB, and the peptides derived 
from HA and gpl20 in TLHAI,  TLHA2 and TLHIV contained 
Arg or Lys residues. Since TMV particle is known to be resis- 
tant to treatment with trypsin [18], it is likely that only the 
sequences locating on the surface of the virus particles are 
digested with trypsin. Proteins of virus particles treated with 
trypsin were examined by Western blot analysis using an anti- 
TMV antiserum. The intact CP in the virus particles was not 
digested with trypsin (Fig. 3A, lanes 4, 6, 8, 10 and 12), and 
purified free CP was completely digested with trypsin (Fig. 3A, 
lane 2). On the other hand, FPs in the virus particles were 
susceptible to trypsin, resulting in shift of their mobility be- 
tween the original FPs and intact CP (Fig. 3A, lanes 6, 8, 10 
and 12). Anti-ACEI, anti-pepl8, anti-pep8 and anti-pepl 3 an- 
tiserum did not bind to the digested FPs (Fig. 3B, lanes 6, 8, 
10 and 12). 
Precipitin reactions were observed specifically between anti- 
ACEI antiserum and TLRTB virus particle, anti-pepl8 antise- 
rum and TLHA1 virus particle, anti-pep8 antiserum and 
TLHA2 virus particle, and anti-pepl3 antiserum and TLHIV 
virus particle, respectively (Fig. 4). These results support the 
notion that foreign peptides of FPs in virus particles are located 
on the surface of the particles, as depicted in Fig. 5. 
4. Discussion 
TMV vectors we have developed can form virus particles and 
the virus particles include both intact CP and FP (Fig. 2). The 
yield of the virus particles is about he same as that of wild-type 
TMV, and propagation and purification of the particles are 
very easy. In addition, no loss of the foreign genes inserted in 
the vectors was observed after three serial passages. Thus this 
Fig. 4. Precipitin reaction (ring test) using anti-ACEI (A), anti-pepl8 
(B), anti-pep8 (C) and anti-pepl 3 (D) antiserum. A layer of antiserum 
was covered with a layer of TLW3 (tube 1), TLRTB (tube 2), TLHA1 
(tube 3), TLHA2 (tube 4) and TLHIV (tube 5) virus particle solution. 
The positions of the precipitin ring are indicated by arrowheads. 
that FPs were CP ACEI, CPpep l  8, CP-pep8 and CP-pepl 3, 
respectively, antiserum against ACEI, pepl8, pep8 and pepl3 
were used to perform Western blot characterization f these 
proteins. Anti-ACEI, anti-pepl8, anti-pep8, and anti-pepl3 
antiserum specifically bound to FPs in TLRTB, TLHA1, 
TLHA2 and TLHIV virus particles, respectively (Fig. 2B). Fur- 
ther purification through sucrose density gradient centrifuga- 
tion [17] did not prevent he FPs from appearing in the virus 
particles (data not shown). Thus FPs are incorporated into the 
particles, and are not just adhering to their surface. The relative 
amount of FP-to-CP included in virus particles was about 1 : 20 
and the same as in leaf extracts. These results indicate that FPs 
are incorporated into the virus particles as efficiently as CP. 
3.4. Properties of  virus particles Fig. 5. A model for the virus particle carrying foreign peptides on the 
To investigate whether the foreign paptides of FPs in virus surface. The foreign peptides of the FPs are indicated by filled circles. 
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type of TMV vector grows stably, and large amounts of virus 
particles can be obtained, indicating that foreign peptides carl 
be as easily purified as virus particles from the inoculated 
plants. 
The most attractive feature of the virus particles is that for- 
eign peptides as long as 21 amino acids can be presented on the 
particle surface (Figs. 3 and 4). We think that this feature makes 
it possible to present an epitope to the immune system and this 
TMV vector system may be a tool for the production of vac- 
cines in plants. 
We are working on increasing read-through efficiency and oil 
determining how large a peptide can be presented on the sur- 
face of the virus particles. 
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